ACTIVE HALF-LIFE: 12 hours
CLASSIFICATION: SARM
DOSAGE: 10mg/Pill
ACNE: NO
WATER RETENTION: No
HBR: No
HEPATOXITY: No
AROMATIZATION: NO
S23 stands out as one of the most potent and robust Selective Androgen Receptor Modulators (SARMs) available in the market, with YK11 being its immediate counterpart.
Derived from the alteration of the chemical structure of a compound known as C-6, S23 represents an enhanced version of C-6, boasting superior bioavailability and binding affinity. With an impressive bioavailability reaching up to 96%, S23’s binding affinity ranks among the highest among all existing SARMs, comparable to LGD-4033.
As a full agonist of the androgen receptor, S23, alongside LGD-4033, holds the unique distinction of possessing this property, contributing to its suppressive nature akin to steroids and potential impact on testosterone levels. It is noteworthy that S23 has exhibited infertility in rats during testing, emphasizing its remarkable potency.
How S23 Works: S23 operates similarly to anabolic steroids but distinguishes itself by its selective action on androgen receptors in muscle tissue, avoiding side effects on other areas such as the prostate, which are common with steroids.
S23 Benefits:
S23 Side Effects:
Dosage and Cycle Length: Commence with a conservative dosage of 5mg daily, gradually adjusting based on individual response, with a maximum of 15mg per day. Given its 12-hour half-life, splitting the daily dose into morning and evening administrations is advisable. Limit cycles to 8 weeks, and prolonged usage is discouraged.
S23 PCT: S23 stands out as the only SARM (potentially alongside YK11) that necessitates a PCT due to its potency. A recommended 4-week PCT with Clomid is advised at the cycle’s conclusion.
Conclusion: While S23 yields substantial benefits, its limited research status underscores the importance of exercising caution. Exploring other well-researched SARMs is advisable before considering S23. Begin with minimal dosages to potentially obviate the need for PCT. Always approach S23 responsibly, acknowledging its potential side effects and respecting its potency.
© 2026 AAS Direct.
Handcrafted Design With â¤ï¸